((R)-N-(2-(3,4-dihydroxyphenyl)-2-hydroxyethyl)-N-methylnitrous amide)

N-Nitroso Epinephrine, chemically identified as (R)-N-(2-(3,4-dihydroxyphenyl)-2-hydroxyethyl)-N-methylnitrous amide, is a nitrosamine impurity that may form from Epinephrine or Epinephrine-related intermediates when the secondary amine group is exposed to nitrosating agents such as nitrite under acidic, oxidative, or moisture-prone conditions. CAS No: 3006789-99-4; Molecular Formula: C9H12N2O4; Molecular Weight: 212.2g/mol.

As a non-volatile, structurally complex nitrosamine, it is considered a high-concern impurity due to potential carcinogenicity associated with N-nitroso functional groups. The USFDA Carcinogenic Potency Categorization Approach (CPCA) places N-Nitroso Epinephrine in Potency Category 4, with a default acceptable intake limit of 1500 ng/day. From a regulatory perspective, N-Nitroso Epinephrine must be assessed as part of nitrosamine risk evaluations required under FDA, EMA, and ICH M7 guidance. Its presence is relevant to nitrosation-pathway analysis, raw-material quality control, excipient nitrite contribution, manufacturing-process assessment, and long-term product stability. Due to the high reactivity and oxidative sensitivity of Epinephrine, additional emphasis is placed on storage, pH control, and avoidance of nitrite sources throughout the manufacturing chain.

At Manasa Life Sciences, we help manufacturers identify, evaluate, and control the risk of N-Nitroso Epinephrine through comprehensive nitrosamine-precursor mapping, assessment of nitrosation-prone steps, and development of ultra-sensitive analytical methods (LC-MS/MS, HRMS). Our expertise supports regulatory compliance, strengthens impurity-control strategies, and enhances product safety across the full pharmaceutical lifecycle.